{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:14:25Z","timestamp":1789496065335,"version":"build-2803163510"},"reference-count":23,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"unspecified","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019832","name":"Gal\u00e1pagos","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019832","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2023,10,9]]},"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The goal of this study was to identify protein and transcriptional biomarkers and pathways associated with baseline disease state, the effect of filgotinib (FIL) treatment on these biomarkers, and to investigate the mechanism of action of FIL on clinical improvement in patients with active psoriatic arthritis (PsA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The phase II EQUATOR (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03101670\">NCT03101670<\/jats:ext-link>) trial evaluated the efficacy of FIL, a Janus kinase 1-preferential inhibitor, in patients with PsA. Peripheral protein and gene expression levels in association with clinical state at baseline and post-treatment were assessed in 121 patients using linear mixed effects models for repeated measures analyses. Mediation analysis and structural equation modelling (SEM) were performed to investigate the mechanism of action of FIL at week 4 on downstream clinical improvement at week 16.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Baseline analyses showed that markers of inflammation were significantly associated with multiple PsA clinical metrics, except for Psoriasis Area and Severity Index (PASI), which corresponded to Th17 markers. FIL treatment resulted in sustained transcriptional inhibition of immune genes and pathways, a sustained increase in B-cell fraction and mature B-cells in circulation, and a transient effect on other cell fractions. Mediation analysis revealed that changes in B cells, systemic inflammatory cytokines and neutrophils at week 4 were associated with changes in clinical metrics at week 16. SEM suggested that FIL improved PASI through reduction of IL-23 p19 and IL-12 p40 proteins.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our results revealed that FIL treatment rapidly downregulates inflammatory and immune pathways associated with PsA disease activity corresponding to clinical improvement in PsA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03101670\">NCT03101670<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2023-003550","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T10:27:22Z","timestamp":1699525642000},"page":"e003550","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Pharmacodynamic effects of filgotinib treatment driving clinical improvement in patients with active psoriatic arthritis enrolled in the EQUATOR trial"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct03101670","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03101670","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03101670","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Vinod","family":"Chandran","sequence":"first","affiliation":[{"name":"Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada"},{"name":"Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladislav A","family":"Malkov","sequence":"additional","affiliation":[{"name":"Clinical Bioinformatics & Exploratory Analytics, Gilead Sciences Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6380-6755","authenticated-orcid":false,"given":"Kaori L","family":"Ito","sequence":"additional","affiliation":[{"name":"Clinical Bioinformatics & Exploratory Analytics, Gilead Sciences Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihua","family":"Liu","sequence":"additional","affiliation":[{"name":"Clinical Bioinformatics & Exploratory Analytics, Gilead Sciences Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene","family":"Vestergaard","sequence":"additional","affiliation":[{"name":"Clinical Bioinformatics & Exploratory Analytics, Gilead Sciences Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oh Kyu","family":"Yoon","sequence":"additional","affiliation":[{"name":"Clinical Bioinformatics & Exploratory Analytics, Gilead Sciences Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfeng","family":"Liu","sequence":"additional","affiliation":[{"name":"Clinical Bioinformatics & Exploratory Analytics, Gilead Sciences Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Trivedi","sequence":"additional","affiliation":[{"name":"Clinical Development, Gilead Sciences Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angie","family":"Hertz","sequence":"additional","affiliation":[{"name":"Biomarker Sciences, Gilead Sciences Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-0592","authenticated-orcid":false,"given":"Dafna","family":"Gladman","sequence":"additional","affiliation":[{"name":"Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada"},{"name":"Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,11,9]]},"reference":[{"key":"2025090313563169000_9.4.e003550.1","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.12688\/f1000research.19144.1","article-title":"Psoriatic arthritis","volume":"8","author":"Ocampo D","year":"2019","journal-title":"F1000Res"},{"key":"2025090313563169000_9.4.e003550.2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2025090313563169000_9.4.e003550.3","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20140712"},{"key":"2025090313563169000_9.4.e003550.4","doi-asserted-by":"crossref","DOI":"10.1038\/nrd.2017.267","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"17","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"2025090313563169000_9.4.e003550.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106210"},{"key":"2025090313563169000_9.4.e003550.6","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Mease","year":"2018","journal-title":"The Lancet"},{"key":"2025090313563169000_9.4.e003550.7","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/rheumatology\/kez408","article-title":"Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR)","volume":"59","author":"Orbai","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313563169000_9.4.e003550.8","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s40744-023-00583-9","article-title":"Filgotinib modulates inflammation-associated peripheral blood protein biomarkers in adults with active rheumatoid arthritis and prior inadequate response to methotrexate","volume":"10","author":"Tanaka","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2025090313563169000_9.4.e003550.9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2174\/157489307780618231","article-title":"Gene set enrichment analysis (GSEA) for interpreting gene expression profiles","volume":"2","author":"Shi","year":"2007","journal-title":"Current Bioinformatics"},{"key":"2025090313563169000_9.4.e003550.10","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkv007","article-title":"Limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2025090313563169000_9.4.e003550.11","doi-asserted-by":"crossref","unstructured":"Tingley D , Yamamoto T , Hirose K , et al . Mediation: R package for causal mediation analysis. 2014. doi:10.18637\/jss.v059.i05","DOI":"10.18637\/jss.v059.i05"},{"key":"2025090313563169000_9.4.e003550.12","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v048.i04"},{"key":"2025090313563169000_9.4.e003550.13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1005766","article-title":"C-reactive protein upregulates the whole blood expression of CD59-an integrative analysis","volume":"13","author":"Lepik","year":"2017","journal-title":"PLoS Comput Biol"},{"key":"2025090313563169000_9.4.e003550.14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.964274","article-title":"Combined\u2013whole blood and skin fibroblasts-transcriptomic analysis in psoriatic arthritis reveals molecular signatures of activity, resistance and early response to treatment","volume":"13","author":"Grivas","year":"2022","journal-title":"Front Immunol"},{"key":"2025090313563169000_9.4.e003550.15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128262","article-title":"Gene expression profiling in peripheral blood cells and synovial membranes of patients with Psoriatic arthritis","volume":"10","author":"Dolcino","year":"2015","journal-title":"PLoS One"},{"key":"2025090313563169000_9.4.e003550.16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/TP.0b013e31818bbea7","article-title":"The effect of the JAK inhibitor CP-690,550 on peripheral immune parameters in stable kidney allograft patients","volume":"87","author":"van Gurp","year":"2009","journal-title":"Transplantation"},{"key":"2025090313563169000_9.4.e003550.17","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2020.607725","article-title":"JAK inhibitors and modulation of B cell immune responses in rheumatoid arthritis","volume":"7","author":"Moura","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"2025090313563169000_9.4.e003550.18","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-81588-8","article-title":"Suppression of IL-23-mediated psoriasis-like inflammation by regulatory B cells","volume":"11","author":"Mizumaki","year":"2021","journal-title":"Sci Rep"},{"key":"2025090313563169000_9.4.e003550.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.10.002"},{"key":"2025090313563169000_9.4.e003550.20","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.727987","article-title":"SOCS proteins in immunity, inflammatory diseases, and immune-related cancer","volume":"8","author":"Sobah","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2025090313563169000_9.4.e003550.21","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-020-02343-4"},{"key":"2025090313563169000_9.4.e003550.22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/cei\/uxac085","article-title":"Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response","volume":"210","author":"Valli","year":"2022","journal-title":"Clin Exp Immunol"},{"key":"2025090313563169000_9.4.e003550.23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.21973"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2023-003550","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:56:39Z","timestamp":1756932999000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2023-003550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,11,9]]},"published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1136\/rmdopen-2023-003550"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2023-003550","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]}}}